TITLE

Sustained-Release Niacin for Prevention of Migraine Headache

AUTHOR(S)
Velling, David A.; Dodick, David W.; Muir, Jesse J.
PUB. DATE
June 2003
SOURCE
Mayo Clinic Proceedings;Jun2003, Vol. 78 Issue 6, p770
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Considerable advances in the diagnosis and treatment of migraine headache have occurred during the past decade, but treatment options for acute migraine attacks have expanded at a faster rate than those for prophylaxis. We describe a patient whose migraine headaches responded dramatically to sustained-release niacin as preventive treatment. Niacin is not generally considered to be effective for migraine prevention. However, low plasma levels of serotonin have been implicated in migraine pathogenesis, and niacin may act as a negative feedback regulator on the kynurenine pathway to shunt tryptophan into the serotonin pathway, thus increasing plasma serotonin levels. Sustained-release niacin merits further study as a potentially useful preventive therapy for migraine headache.
ACCESSION #
10544720

 

Related Articles

  • Oral drug for migraine attacks.  // Modern Medicine;Apr98, Vol. 66 Issue 4, p58 

    Introduces Naratriptan HCl, a 5-hydroxytryptamine (5-HT1) antagonist for the treatment of acute migraine from Gloxo-Wellcome company. Mechanism of action of the drug; Contraindication; Adverse effects.

  • Serotonin: A key to migraine disorders?  // Nutrition Health Review: The Consumer's Medical Journal;1994, Issue 70, p6 

    Speculates on the role of serotonin in preventing the occurrence of migraine headaches. Constriction of blood vessels; Increase in blood serotonin after vomiting; Dietary sources of serotonin; Hormonal influences.

  • Batters up. Portyansky, Elena // Drug Topics;9/1/97, Vol. 141 Issue 17, p27 

    Focuses on the drug Niaspan, the extended-release form of niacin. Approval of Niaspan for prescription sales; Problems which the drug is designed to treat; Attributes of the drug.

  • Statin/niacin combination produces dramatic increase in HDL cholesterol.  // Formulary;May2000, Vol. 35 Issue 5, p445 

    Reports that a combination of statin and niacin increases high-density lipoprotein cholesterol. Clinical tests results; Risk factors; Potential place of Nicostatin in therapy.

  • Extended-Release Niacin for Type 2 Diabetes Dyslipidemia. Sadovsky, Richard // American Family Physician;11/15/2002, Vol. 66 Issue 10, p1980 

    Evaluates the safety and efficacy of low-dose extended-release niacin in managing dyslipidemia in patients with diabetes mellitus. Patients included in the study; Liver enzyme levels of the patients.

  • Enfuvirtide/niacin interaction.  // Reactions Weekly;1/22/2011, Issue 1335, p19 

    The article describes the case report of an interaction of enfuvirtide and niacin in a patient with HIV infection.

  • Niacin Compared with Ezetimibe. Lindsay, Alistair C.; Halcox, Julian P. // New England Journal of Medicine;3/18/2010, Vol. 362 Issue 11, p1046 

    A letter to the editor is presented in response to an article about the use of extended-release niacin to treat hypertension by Allen J. Taylor in the November 26, 2009 issue.

  • Niacin Compared with Ezetimibe. Duivenvoorden, Rapha�l; Vergeer, Menno; Kastelein, John J. P. // New England Journal of Medicine;3/18/2010, Vol. 362 Issue 11, p1046 

    A letter to the editor is presented in response to an article about the use of extended-release niacin to treat hypertension by Allen J. Taylor in the November 26, 2009 issue.

  • Niacin Compared with Ezetimibe. Weiss, Stanley H. // New England Journal of Medicine;3/18/2010, Vol. 362 Issue 11, p1046 

    A letter to the editor is presented in response to an article about the use of extended-release niacin to treat hypertension by Allen J. Taylor in the November 26, 2009 issue.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics